Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonist GSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rate Expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys at GSK’s peak sales guidance of >$2.7 billion as early as 2029 Year-end 2025 cash and investments of ~$311 millionSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided...

WARRENVILLE, Ill., March 03, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of achievement for Fuel Tech, highlighted by a resurgence at our FUEL CHEM® operations that produced the highest annual segment revenue since 2018, a broadened opportunity landscape at our Air Pollution Control (“APC”) business segment driven in large part by the expected growth of power generation to support data center construction and operation, and measurable progress at our Dissolved Gas Infusion (“DGI”) business segment,” said Vincent J. Arnone, President and CEO....

Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029ZUG, Switzerland, March 3, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology,...

Total Revenue Growth of 25.3% Year Over Year in the Fourth Quarter Same Store Sales Growth of 9.3% Year Over Year in the Fourth Quarter Opened 12 New Stores in the Fourth Quarter SCOTTSDALE, Ariz., March 03, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (Nasdaq: BRCB) (“Black Rock Coffee Bar” or the “Company”) today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter 2025 HighlightsOpened 12 new stores during the period Total revenue of $53.6 million, up 25.3% compared to the prior year period Same Store Sales Growth(1) increased 9.3% compared to the prior year period Income (loss) from operations of $1.8 million compared to $(0.1) million in the prior year period. In the fourth quarter of 2025, income from operations margin was 3.3% Store-Level Profit(2) of $15.7 million as compared...

Delivered 9th consecutive year of profitability with net income of $76.7 million, or 10.8% margin Net Income increased 22%, or $13.9 million, compared to 2024 Generated $200 million in Cash from Operations in 2025 Paid subscribers increased over 4% to just over 3.09 million, compared to 2024  2025 revenue of $708.8 million, a less than 1% decline compared to 2024 SOUTH JORDAN, Utah, March 03, 2026 (GLOBE NEWSWIRE) — Cricut, Inc. (“Cricut”) (NASDAQ: CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced financial results for its fourth quarter and full year ended December 31, 2025. “While we are pleased with increased profitability with net income up 22%, the over 4% increase in paid subscribers, and positive machine-sell out units in both North...

– Total net sales of $146.6 million versus $145.4 million in prior year fourth quarter –– Net income of $3.5 million versus $2.1 million in prior year fourth quarter –– EBITDA of $8.6 million versus $7.3 million in prior year fourth quarter –– Provides full-year outlook – ST. PETERSBURG, Fla., March 03, 2026 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its fourth quarter 2025 results. “We finished the year with a solid fourth quarter, growing our consolidated revenues while simultaneously reducing expenses which resulted in 19% year-over-year EBITDA growth and earnings per share that nearly doubled,” said Michael Benstock, Chief Executive Officer.  “In addition, our quarterly results again demonstrated the back-end weighted nature of our business, with 6% sequential...

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England Journal of Medicine published positive 12-week clinical results of the UP421 type 1 diabetes study Incorporating the tested hypoimmune technology to develop SC451, a hypoimmune-modified, stem cell-derived therapy, as a one-time treatment for patients with type 1 diabetes, with a goal of normal blood glucose, with no insulin and no immunosuppression Made significant progress with SC451 across manufacturing, regulatory, and clinical trial preparedness, including the non-clinical testing plan and manufacture of the master cell bank Expect to file investigational...